Login
MannKind Corporation NASDAQ: MNKD
MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes
| Name | MannKind Corporation |
| Ticker | MNKD |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Price | 3.54 |
| 52W Low/High | 0.84 / 4.04 |
| Market cap | 811 M |
| 1Y Total Return |
101.14%
Strong |
| 1Y Volatility |
80.07%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
MannKind Corporation is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes
Details
| Ticker | MNKD |
| Name | MannKind Corporation |
| ISIN | |
| CUSIP | 56400P201 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Diabetes |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/22/21
| Close Price | 3.54 |
| 52W Low/High | 0.84 / 4.04 |
| Market cap | 811 M |
| 1Y Total Return |
101.14%
Strong |
| 1Y Volatility |
80.07%
More Risk |
| Beta | 1.56 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -71.9% |
| Cash from Op. / Cur. Liabilities | -0.32 |
| Diluted Earnings / Share | -0.21 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 13.0 |
| Price / Book | -4.4 |
| Price / CF | -24.3 |
| Current Ratio | 0.6 |
| Cur.Liabilities / Tot.Liabilities | 0.4 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
63
|
63
|
16
|
20
|
162
|
0
|
|
| Gross Profit |
37
|
36
|
-
|
-
|
77
|
-
|
|
| R&D |
7
|
6
|
11
|
12
|
20
|
41
|
|
| EBITDA |
-33
|
-35
|
-95
|
-13
|
-180
|
-88
|
|
| Operating Income |
-29
|
-47
|
-99
|
-86
|
-188
|
-102
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
230
|
200
|
154
|
105
|
97
|
81
|
|
| EPS exc. Extra |
-0.21
|
-0.24
|
-0.86
|
-0.26
|
-2.70
|
-1.62
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
96
|
95
|
45
|
56
|
96
|
278
|
|
| Cash, Eq & Invt ShortTerm |
53
|
50
|
11
|
20
|
36
|
33
|
|
| Total Current Assets |
66
|
62
|
20
|
29
|
49
|
71
|
|
| Total Non-Current Assets |
29
|
33
|
26
|
28
|
48
|
207
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
282
|
280
|
251
|
307
|
335
|
403
|
|
| Total Current Liabilities |
106
|
64
|
60
|
91
|
106
|
267
|
|
| Long Term Debt |
176
|
216
|
191
|
216
|
229
|
135
|
|
| Shareholder equity |
-186
|
-185
|
-205
|
-251
|
-239
|
-125
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-33
|
-58
|
-93
|
-48
|
-88
|
-70
|
|
| Depreciation |
3
|
2
|
3
|
4
|
6
|
13
|
|
| Cash from Investing |
19
|
-23
|
0
|
17
|
-1
|
-24
|
|
| Capex |
0
|
3
|
0
|
0
|
1
|
24
|
|
| Cash from Financing |
36
|
101
|
84
|
15
|
92
|
-45
|
|
| Stock Issued |
34
|
44
|
90
|
0
|
102
|
30
|
|
| Debt (LT) Issued |
5
|
60
|
-2
|
15
|
-6
|
-64
|
|
| Free Cash Flow |
8
|
-45
|
-128
|
4
|
-359
|
-164
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
0.6
|
1.0
|
0.3
|
0.3
|
0.5
|
0.3
|
|
| Financial Leverage D/E |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available